Stoke Therapeutics (STOK) Share-based Compensation (2018 - 2026)
Stoke Therapeutics' quarterly Share-based Compensation came in at $8.8 million in Q1 2026, up 29.62% year-on-year from $6.8 million in Q1 2025, and down 10.77% quarter-over-quarter from $9.8 million in Q4 2025.
Stoke Therapeutics has reported Share-based Compensation for 9 years, with the latest figure at $8.8 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 29.62% year-over-year to $8.8 million; the trailing twelve-month figure through Mar 2026 stood at $34.2 million (up 18.57% YoY), and the FY2025 full-year result was $32.2 million, up 17.09% from the prior year.
- Share-based Compensation for Q1 2026 stood at $8.8 million, down from $9.8 million in the prior quarter.
- The five-year high for Share-based Compensation was $9.8 million in Q4 2025, with the low at $5.0 million in Q1 2022.
- Average Share-based Compensation over 5 years is $6.9 million, with a median of $6.8 million recorded in 2025.
- Year-over-year, Share-based Compensation jumped 6118.75% in 2022 and slipped 8.1% in 2024.
- Tracing STOK's Share-based Compensation over 5 years: stood at $5.8 million in 2022, then gained by 4.63% to $6.1 million in 2023, then increased by 18.34% to $7.2 million in 2024, then soared by 36.84% to $9.8 million in 2025, then decreased by 10.77% to $8.8 million in 2026.
- The last three Share-based Compensation figures came in at $8.8 million (Q1 2026), $9.8 million (Q4 2025), and $8.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Stoke Therapeutics | 1.92 Bn | 1.92 Bn | - | 8.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 8.75 Mn |
| Mar 31, 2026 | 8.75 Mn |
| Dec 31, 2025 | 9.81 Mn |
| Dec 31, 2025 | 9.81 Mn |
| Sep 30, 2025 | 8.04 Mn |
| Sep 30, 2025 | 8.04 Mn |
| Jun 30, 2025 | 7.60 Mn |
| Jun 30, 2025 | 7.60 Mn |
| Mar 31, 2025 | 6.75 Mn |
| Mar 31, 2025 | 6.75 Mn |
| Dec 31, 2024 | 7.17 Mn |
| Dec 31, 2024 | 7.17 Mn |
| Sep 30, 2024 | 7.49 Mn |
| Sep 30, 2024 | 7.49 Mn |
| Jun 30, 2024 | 7.43 Mn |
| Jun 30, 2024 | 7.43 Mn |
| Mar 31, 2024 | 5.41 Mn |
| Mar 31, 2024 | 5.41 Mn |
| Dec 31, 2023 | 6.06 Mn |
| Dec 31, 2023 | 6.06 Mn |
| Sep 30, 2023 | 6.55 Mn |
| Sep 30, 2023 | 6.55 Mn |
| Jun 30, 2023 | 6.76 Mn |
| Jun 30, 2023 | 6.76 Mn |
| Mar 31, 2023 | 5.89 Mn |
| Mar 31, 2023 | 5.89 Mn |
| Dec 31, 2022 | 5.79 Mn |
| Dec 31, 2022 | 5.79 Mn |
| Sep 30, 2022 | 5.93 Mn |
| Sep 30, 2022 | 5.93 Mn |
| Jun 30, 2022 | 6.16 Mn |
| Jun 30, 2022 | 6.16 Mn |
| Mar 31, 2022 | 4.98 Mn |
| Mar 31, 2022 | 4.98 Mn |
| Dec 31, 2021 | 4.69 Mn |
| Dec 31, 2021 | 4.69 Mn |
| Sep 30, 2021 | 4.61 Mn |
| Sep 30, 2021 | 4.61 Mn |
| Jun 30, 2021 | 4.45 Mn |
| Jun 30, 2021 | 4.45 Mn |
| Mar 31, 2021 | 80,000.00 |
| Mar 31, 2021 | 80,000.00 |
| Dec 31, 2020 | 1.61 Mn |
| Dec 31, 2020 | 1.61 Mn |
| Sep 30, 2020 | 1.79 Mn |
| Sep 30, 2020 | 1.79 Mn |
| Jun 30, 2020 | 1.65 Mn |
| Jun 30, 2020 | 1.65 Mn |
| Mar 31, 2020 | 754,000.00 |
| Mar 31, 2020 | 754,000.00 |
| Dec 31, 2019 | 712,000.00 |
| Dec 31, 2019 | 712,000.00 |
| Sep 30, 2019 | 731,000.00 |
| Sep 30, 2019 | 731,000.00 |
| Jun 30, 2019 | 298,000.00 |
| Jun 30, 2019 | 298,000.00 |
| Mar 31, 2019 | 181,000.00 |
| Mar 31, 2019 | 181,000.00 |
| Dec 31, 2018 | 119,000.00 |
| Dec 31, 2018 | 119,000.00 |
| Sep 30, 2018 | 40,000.00 |
| Sep 30, 2018 | 40,000.00 |
| Jun 30, 2018 | 77,000.00 |
| Jun 30, 2018 | 77,000.00 |